BioNTech's founders plan their third startup

I’ve also been following the BioNTech announcement that co-founders Ugur Sahin and Özlem Türeci will leave the company by year-end to start a new biotech focused on next-generation mRNA therapeutics (their third startup). The stock dropped over 20%, partly because no successors were named, and partly because BioNTech is on the cusp of multiple late-stage cancer therapy readouts.